Antioxidants (Mar 2022)

Is Nucleoredoxin a Master Regulator of Cellular Redox Homeostasis? Its Implication in Different Pathologies

  • Osiris Germán Idelfonso-García,
  • Brisa Rodope Alarcón-Sánchez,
  • Verónica Rocío Vásquez-Garzón,
  • Rafael Baltiérrez-Hoyos,
  • Saúl Villa-Treviño,
  • Pablo Muriel,
  • Héctor Serrano,
  • Julio Isael Pérez-Carreón,
  • Jaime Arellanes-Robledo

DOI
https://doi.org/10.3390/antiox11040670
Journal volume & issue
Vol. 11, no. 4
p. 670

Abstract

Read online

Nucleoredoxin (NXN), an oxidoreductase enzyme, contributes to cellular redox homeostasis by regulating different signaling pathways in a redox-dependent manner. By interacting with seven proteins so far, namely disheveled (DVL), protein phosphatase 2A (PP2A), phosphofructokinase-1 (PFK1), translocation protein SEC63 homolog (SEC63), myeloid differentiation primary response gene-88 (MYD88), flightless-I (FLII), and calcium/calmodulin-dependent protein kinase II type alpha (CAMK2A), NXN is involved in the regulation of several key cellular processes, including proliferation, organogenesis, cell cycle progression, glycolysis, innate immunity and inflammation, motility, contraction, protein transport into the endoplasmic reticulum, neuronal plasticity, among others; as a result, NXN has been implicated in different pathologies, such as cancer, alcoholic and polycystic liver disease, liver fibrogenesis, obesity, Robinow syndrome, diabetes mellitus, Alzheimer’s disease, and retinitis pigmentosa. Together, this evidence places NXN as a strong candidate to be a master redox regulator of cell physiology and as the hub of different redox-sensitive signaling pathways and associated pathologies. This review summarizes and discusses the current insights on NXN-dependent redox regulation and its implication in different pathologies.

Keywords